- $9.91m
- $7.65m
- $19.19m
- 57
- 64
- 37
- 52
Annual income statement for cbdMD, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 44.5 | 35.4 | 24.2 | 19.5 | 19.2 |
| Cost of Revenue | |||||
| Gross Profit | 30 | 22.3 | 15 | 12 | 12 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 69.3 | 106 | 46.5 | 22.7 | 21.4 |
| Operating Profit | -24.8 | -70.4 | -22.3 | -3.24 | -2.16 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -24.3 | -70.1 | -22.9 | -3.7 | -2.04 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.4 | -70.1 | -22.9 | -3.7 | -2.04 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -23.4 | -70.1 | -22.9 | -3.7 | -2.04 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -25.9 | -74.1 | -26.9 | -7.7 | -4.38 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -148 | -127 | -55 | -14.4 | -1.18 |